[Federal Register Volume 87, Number 143 (Wednesday, July 27, 2022)]
[Proposed Rules]
[Page 45076]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-16102]
[[Page 45076]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA-623]
Schedules of Controlled Substances: Placement of 4-hydroxy-N,N-
diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-
MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-
methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-
diisopropyltryptamine (DiPT) in Schedule I; Withdrawal of Proposed Rule
and Notice of Hearing
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Withdrawal of proposed rule and withdrawal of notice of
hearing.
-----------------------------------------------------------------------
SUMMARY: The Drug Enforcement Administration (DEA) is withdrawing a
proposed rule that was published in the Federal Register on January 14,
2022, which proposed to place five tryptamine hallucinogens in schedule
I of the Controlled Substances Act. Upon further consideration, DEA has
determined that it is appropriate to submit a new request to the
Department of Health and Human Services (HHS) for an updated scientific
and medical evaluation and scheduling recommendation for these
substances. Accordingly, DEA is withdrawing the proposed rule and
notice of hearing that was published in the Federal Register on July 6,
2022, and is canceling the public hearing and terminating the pending
hearing proceedings. DEA may issue a new proposed rule in the future
regarding these substances if warranted.
DATES: The proposed rule that was published in the Federal Register on
January 14, 2022 (87 FR 2376) is withdrawn as of July 27, 2022. The
notice of hearing on the proposed rule that was published in the
Federal Register on July 6, 2022 (87 FR 40167) is withdrawn as of July
27, 2022. The public hearing, originally scheduled to commence on
August 22, 2022, is cancelled, and all proceedings related thereto are
terminated.
FOR FURTHER INFORMATION CONTACT: Terrence L. Boos, Ph.D., Chief, Drug
and Chemical Evaluation Section, Diversion Control Division, Drug
Enforcement Administration; Mailing Address: 8701 Morrissette Drive,
Springfield, Virginia 22152; Telephone: (571) 362-3249.
SUPPLEMENTARY INFORMATION: On January 14, 2022, DEA published a Notice
of Proposed Rulemaking (NPRM) in the Federal Register (87 FR 2376) to
place five tryptamine hallucinogens--specifically, 4-hydroxy-N,N-
diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-
MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-
methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-
diisopropyltryptamine (DiPT)--in schedule I of the Controlled
Substances Act (CSA) (21 U.S.C. 801, et seq.). The proposed placement
of these substances in schedule I was based on the scientific and
medical evaluations and recommendations that the HHS provided to DEA.
In response to the NPRM, DEA received numerous comments and four
requests for a hearing on the proposed rule, as provided in 21 U.S.C.
811(a). DEA scheduled a hearing on the proposed rule and published a
notice to that effect in the Federal Register on July 6, 2022 (87 FR
40167). The public hearing was scheduled to commence on August 22,
2022.
Upon further consideration, DEA has determined that it is
appropriate to submit a new request to HHS for an updated scientific
and medical evaluation and scheduling recommendation for these
substances in accordance with 21 U.S.C. 811(b) and 21 CFR 1308.43(d).
Accordingly, DEA's proposed rule published in the Federal Register
on January 14, 2022 (87 FR 2376), and the notice of hearing on the
proposed rule published in the Federal Register on July 6, 2022 (87 FR
40167), are withdrawn. The public hearing scheduled to commence on
August 22, 2022 is canceled, and all proceedings related thereto are
hereby terminated. DEA may issue a new proposed rule in the future
regarding the five tryptamine hallucinogens if warranted.
Signing Authority
This document of the Drug Enforcement Administration was signed on
July 22, 2022, by Administrator Anne Milgram. That document with the
original signature and date is maintained by DEA. For administrative
purposes only, and in compliance with requirements of the Office of the
Federal Register, the undersigned DEA Federal Register Liaison Officer
has been authorized to sign and submit the document in electronic
format for publication, as an official document of DEA. This
administrative process in no way alters the legal effect of this
document upon publication in the Federal Register.
Scott Brinks,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2022-16102 Filed 7-26-22; 8:45 am]
BILLING CODE 4410-09-P